vs
Side-by-side financial comparison of Hilltop Holdings Inc. (HTH) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $158.6M, roughly 1.9× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 13.0%, a 58.2% gap on every dollar of revenue.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
HTH vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $300.5M | $158.6M |
| Net Profit | $39.0M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | — | 70.2% |
| Net Margin | 13.0% | 71.2% |
| Revenue YoY | — | 3661.1% |
| Net Profit YoY | -12.4% | 528.0% |
| EPS (diluted) | $0.64 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $300.5M | — | ||
| Q4 25 | $329.9M | — | ||
| Q3 25 | $330.2M | — | ||
| Q2 25 | $303.3M | — | ||
| Q1 25 | $318.5M | $158.6M | ||
| Q4 24 | $301.1M | $22.6M | ||
| Q3 24 | $305.5M | — | ||
| Q2 24 | $297.0M | — |
| Q1 26 | $39.0M | — | ||
| Q4 25 | $41.6M | — | ||
| Q3 25 | $45.8M | — | ||
| Q2 25 | $36.1M | — | ||
| Q1 25 | $42.1M | $112.9M | ||
| Q4 24 | $35.5M | $-10.5M | ||
| Q3 24 | $29.7M | — | ||
| Q2 24 | $20.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | 16.1% | — | ||
| Q3 25 | 18.4% | — | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 18.1% | 70.2% | ||
| Q4 24 | 14.7% | -60.4% | ||
| Q3 24 | 13.9% | — | ||
| Q2 24 | 10.0% | — |
| Q1 26 | 13.0% | — | ||
| Q4 25 | 12.6% | — | ||
| Q3 25 | 13.9% | — | ||
| Q2 25 | 11.9% | — | ||
| Q1 25 | 13.2% | 71.2% | ||
| Q4 24 | 11.8% | -46.4% | ||
| Q3 24 | 9.7% | — | ||
| Q2 24 | 6.8% | — |
| Q1 26 | $0.64 | — | ||
| Q4 25 | $0.68 | — | ||
| Q3 25 | $0.74 | — | ||
| Q2 25 | $0.57 | — | ||
| Q1 25 | $0.65 | $1.90 | ||
| Q4 24 | $0.55 | $-0.15 | ||
| Q3 24 | $0.46 | — | ||
| Q2 24 | $0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $274.8M |
| Total DebtLower is stronger | $990.8M | — |
| Stockholders' EquityBook value | $2.2B | $350.1M |
| Total Assets | $15.7B | $406.9M |
| Debt / EquityLower = less leverage | 0.46× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $990.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | $350.1M | ||
| Q4 24 | $2.2B | $229.0M | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.1B | — |
| Q1 26 | $15.7B | — | ||
| Q4 25 | $15.8B | — | ||
| Q3 25 | $15.6B | — | ||
| Q2 25 | $15.4B | — | ||
| Q1 25 | $15.8B | $406.9M | ||
| Q4 24 | $16.3B | $271.6M | ||
| Q3 24 | $15.9B | — | ||
| Q2 24 | $15.6B | — |
| Q1 26 | 0.46× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-38.7M | — | ||
| Q3 25 | $273.0M | — | ||
| Q2 25 | $-234.6M | — | ||
| Q1 25 | $5.8M | $131.8M | ||
| Q4 24 | $273.9M | $-23.2M | ||
| Q3 24 | $515.6M | — | ||
| Q2 24 | $-435.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-55.5M | — | ||
| Q3 25 | $271.0M | — | ||
| Q2 25 | $-234.6M | — | ||
| Q1 25 | $5.0M | $131.7M | ||
| Q4 24 | $266.8M | $-23.2M | ||
| Q3 24 | $513.8M | — | ||
| Q2 24 | $-437.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | -16.8% | — | ||
| Q3 25 | 82.1% | — | ||
| Q2 25 | -77.4% | — | ||
| Q1 25 | 1.6% | 83.0% | ||
| Q4 24 | 88.6% | -102.7% | ||
| Q3 24 | 168.2% | — | ||
| Q2 24 | -147.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.1% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | 0.1% | ||
| Q4 24 | 2.4% | 0.2% | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.93× | — | ||
| Q3 25 | 5.96× | — | ||
| Q2 25 | -6.50× | — | ||
| Q1 25 | 0.14× | 1.17× | ||
| Q4 24 | 7.71× | — | ||
| Q3 24 | 17.36× | — | ||
| Q2 24 | -21.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
STOK
Segment breakdown not available.
